nodes	percent_of_prediction	percent_of_DWPC	metapath
Rabeprazole—ABCG2—Teniposide—lymphatic system cancer	0.159	0.218	CbGbCtD
Rabeprazole—ABCG2—Mitoxantrone—lymphatic system cancer	0.111	0.152	CbGbCtD
Rabeprazole—CYP1A2—Carmustine—lymphatic system cancer	0.0974	0.134	CbGbCtD
Rabeprazole—ABCG2—Vincristine—lymphatic system cancer	0.0764	0.105	CbGbCtD
Rabeprazole—CYP2C19—Teniposide—lymphatic system cancer	0.071	0.0973	CbGbCtD
Rabeprazole—CYP2C9—Teniposide—lymphatic system cancer	0.059	0.0809	CbGbCtD
Rabeprazole—ABCG2—Methotrexate—lymphatic system cancer	0.0463	0.0634	CbGbCtD
Rabeprazole—CYP3A4—Cytarabine—lymphatic system cancer	0.0348	0.0477	CbGbCtD
Rabeprazole—CYP3A4—Teniposide—lymphatic system cancer	0.0343	0.047	CbGbCtD
Rabeprazole—CYP3A4—Mitoxantrone—lymphatic system cancer	0.024	0.0329	CbGbCtD
Rabeprazole—CYP3A4—Vincristine—lymphatic system cancer	0.0165	0.0226	CbGbCtD
Rabeprazole—Vaginal infection—Methotrexate—lymphatic system cancer	0.00035	0.0013	CcSEcCtD
Rabeprazole—Malnutrition—Carmustine—lymphatic system cancer	0.00035	0.0013	CcSEcCtD
Rabeprazole—Erythema—Carmustine—lymphatic system cancer	0.00035	0.0013	CcSEcCtD
Rabeprazole—Cough—Bleomycin—lymphatic system cancer	0.00035	0.0013	CcSEcCtD
Rabeprazole—Angiopathy—Vincristine—lymphatic system cancer	0.000348	0.00129	CcSEcCtD
Rabeprazole—Diarrhoea—Teniposide—lymphatic system cancer	0.000348	0.00129	CcSEcCtD
Rabeprazole—Chest pain—Bleomycin—lymphatic system cancer	0.000342	0.00126	CcSEcCtD
Rabeprazole—Myalgia—Bleomycin—lymphatic system cancer	0.000342	0.00126	CcSEcCtD
Rabeprazole—Alopecia—Vincristine—lymphatic system cancer	0.000339	0.00126	CcSEcCtD
Rabeprazole—Coma—Methotrexate—lymphatic system cancer	0.000339	0.00125	CcSEcCtD
Rabeprazole—Back pain—Carmustine—lymphatic system cancer	0.000339	0.00125	CcSEcCtD
Rabeprazole—Discomfort—Bleomycin—lymphatic system cancer	0.000338	0.00125	CcSEcCtD
Rabeprazole—Chills—Mitoxantrone—lymphatic system cancer	0.000336	0.00124	CcSEcCtD
Rabeprazole—Ecchymosis—Methotrexate—lymphatic system cancer	0.000336	0.00124	CcSEcCtD
Rabeprazole—Urine output increased—Methotrexate—lymphatic system cancer	0.000336	0.00124	CcSEcCtD
Rabeprazole—Mouth ulceration—Methotrexate—lymphatic system cancer	0.000336	0.00124	CcSEcCtD
Rabeprazole—Bladder pain—Methotrexate—lymphatic system cancer	0.000336	0.00124	CcSEcCtD
Rabeprazole—Neoplasm—Methotrexate—lymphatic system cancer	0.000336	0.00124	CcSEcCtD
Rabeprazole—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.000334	0.00124	CcSEcCtD
Rabeprazole—Gynaecomastia—Methotrexate—lymphatic system cancer	0.000332	0.00123	CcSEcCtD
Rabeprazole—Alopecia—Mitoxantrone—lymphatic system cancer	0.000331	0.00122	CcSEcCtD
Rabeprazole—Confusional state—Bleomycin—lymphatic system cancer	0.00033	0.00122	CcSEcCtD
Rabeprazole—Vision blurred—Carmustine—lymphatic system cancer	0.00033	0.00122	CcSEcCtD
Rabeprazole—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000329	0.00122	CcSEcCtD
Rabeprazole—Tremor—Carmustine—lymphatic system cancer	0.000328	0.00121	CcSEcCtD
Rabeprazole—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000327	0.00121	CcSEcCtD
Rabeprazole—Oedema—Bleomycin—lymphatic system cancer	0.000327	0.00121	CcSEcCtD
Rabeprazole—Erythema—Mitoxantrone—lymphatic system cancer	0.000326	0.0012	CcSEcCtD
Rabeprazole—Anaemia—Carmustine—lymphatic system cancer	0.000324	0.0012	CcSEcCtD
Rabeprazole—Back pain—Vincristine—lymphatic system cancer	0.000323	0.0012	CcSEcCtD
Rabeprazole—Vomiting—Teniposide—lymphatic system cancer	0.000323	0.0012	CcSEcCtD
Rabeprazole—Agitation—Carmustine—lymphatic system cancer	0.000322	0.00119	CcSEcCtD
Rabeprazole—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000321	0.00119	CcSEcCtD
Rabeprazole—Asthenia—Fludarabine—lymphatic system cancer	0.00032	0.00119	CcSEcCtD
Rabeprazole—Rash—Teniposide—lymphatic system cancer	0.00032	0.00119	CcSEcCtD
Rabeprazole—Dermatitis—Teniposide—lymphatic system cancer	0.00032	0.00118	CcSEcCtD
Rabeprazole—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000319	0.00118	CcSEcCtD
Rabeprazole—Headache—Teniposide—lymphatic system cancer	0.000318	0.00118	CcSEcCtD
Rabeprazole—Pruritus—Fludarabine—lymphatic system cancer	0.000316	0.00117	CcSEcCtD
Rabeprazole—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.000316	0.00117	CcSEcCtD
Rabeprazole—Back pain—Mitoxantrone—lymphatic system cancer	0.000315	0.00117	CcSEcCtD
Rabeprazole—Leukopenia—Carmustine—lymphatic system cancer	0.000314	0.00116	CcSEcCtD
Rabeprazole—Anorexia—Bleomycin—lymphatic system cancer	0.000312	0.00115	CcSEcCtD
Rabeprazole—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.000311	0.00115	CcSEcCtD
Rabeprazole—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.00031	0.00115	CcSEcCtD
Rabeprazole—Anaemia—Vincristine—lymphatic system cancer	0.000309	0.00114	CcSEcCtD
Rabeprazole—Agitation—Vincristine—lymphatic system cancer	0.000307	0.00114	CcSEcCtD
Rabeprazole—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000307	0.00114	CcSEcCtD
Rabeprazole—Polyuria—Methotrexate—lymphatic system cancer	0.000307	0.00114	CcSEcCtD
Rabeprazole—Photosensitivity—Methotrexate—lymphatic system cancer	0.000307	0.00114	CcSEcCtD
Rabeprazole—Hypotension—Bleomycin—lymphatic system cancer	0.000306	0.00113	CcSEcCtD
Rabeprazole—Diarrhoea—Fludarabine—lymphatic system cancer	0.000306	0.00113	CcSEcCtD
Rabeprazole—Convulsion—Carmustine—lymphatic system cancer	0.000303	0.00112	CcSEcCtD
Rabeprazole—Hypertension—Carmustine—lymphatic system cancer	0.000302	0.00112	CcSEcCtD
Rabeprazole—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000302	0.00112	CcSEcCtD
Rabeprazole—Nausea—Teniposide—lymphatic system cancer	0.000302	0.00112	CcSEcCtD
Rabeprazole—Anaemia—Mitoxantrone—lymphatic system cancer	0.000301	0.00111	CcSEcCtD
Rabeprazole—Vertigo—Vincristine—lymphatic system cancer	0.0003	0.00111	CcSEcCtD
Rabeprazole—Leukopenia—Vincristine—lymphatic system cancer	0.000299	0.00111	CcSEcCtD
Rabeprazole—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000298	0.0011	CcSEcCtD
Rabeprazole—Chest pain—Carmustine—lymphatic system cancer	0.000298	0.0011	CcSEcCtD
Rabeprazole—Myalgia—Carmustine—lymphatic system cancer	0.000298	0.0011	CcSEcCtD
Rabeprazole—Anxiety—Carmustine—lymphatic system cancer	0.000297	0.0011	CcSEcCtD
Rabeprazole—Paraesthesia—Bleomycin—lymphatic system cancer	0.000294	0.00109	CcSEcCtD
Rabeprazole—Malaise—Mitoxantrone—lymphatic system cancer	0.000294	0.00109	CcSEcCtD
Rabeprazole—Dyspnoea—Bleomycin—lymphatic system cancer	0.000292	0.00108	CcSEcCtD
Rabeprazole—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000291	0.00108	CcSEcCtD
Rabeprazole—Convulsion—Vincristine—lymphatic system cancer	0.00029	0.00107	CcSEcCtD
Rabeprazole—Hypertension—Vincristine—lymphatic system cancer	0.000289	0.00107	CcSEcCtD
Rabeprazole—Confusional state—Carmustine—lymphatic system cancer	0.000288	0.00107	CcSEcCtD
Rabeprazole—Oedema—Carmustine—lymphatic system cancer	0.000286	0.00106	CcSEcCtD
Rabeprazole—Decreased appetite—Bleomycin—lymphatic system cancer	0.000285	0.00105	CcSEcCtD
Rabeprazole—Myalgia—Vincristine—lymphatic system cancer	0.000285	0.00105	CcSEcCtD
Rabeprazole—Cough—Mitoxantrone—lymphatic system cancer	0.000284	0.00105	CcSEcCtD
Rabeprazole—Vomiting—Fludarabine—lymphatic system cancer	0.000284	0.00105	CcSEcCtD
Rabeprazole—Convulsion—Mitoxantrone—lymphatic system cancer	0.000282	0.00104	CcSEcCtD
Rabeprazole—Rash—Fludarabine—lymphatic system cancer	0.000282	0.00104	CcSEcCtD
Rabeprazole—Dermatitis—Fludarabine—lymphatic system cancer	0.000281	0.00104	CcSEcCtD
Rabeprazole—Hypertension—Mitoxantrone—lymphatic system cancer	0.000281	0.00104	CcSEcCtD
Rabeprazole—Pain—Bleomycin—lymphatic system cancer	0.00028	0.00104	CcSEcCtD
Rabeprazole—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00028	0.00104	CcSEcCtD
Rabeprazole—Headache—Fludarabine—lymphatic system cancer	0.00028	0.00104	CcSEcCtD
Rabeprazole—Tachycardia—Carmustine—lymphatic system cancer	0.000279	0.00103	CcSEcCtD
Rabeprazole—Myalgia—Mitoxantrone—lymphatic system cancer	0.000277	0.00103	CcSEcCtD
Rabeprazole—Chest pain—Mitoxantrone—lymphatic system cancer	0.000277	0.00103	CcSEcCtD
Rabeprazole—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000277	0.00103	CcSEcCtD
Rabeprazole—Anxiety—Mitoxantrone—lymphatic system cancer	0.000276	0.00102	CcSEcCtD
Rabeprazole—Discomfort—Mitoxantrone—lymphatic system cancer	0.000274	0.00101	CcSEcCtD
Rabeprazole—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000273	0.00101	CcSEcCtD
Rabeprazole—Oedema—Vincristine—lymphatic system cancer	0.000273	0.00101	CcSEcCtD
Rabeprazole—Anorexia—Carmustine—lymphatic system cancer	0.000272	0.00101	CcSEcCtD
Rabeprazole—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00027	0.000998	CcSEcCtD
Rabeprazole—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000269	0.000997	CcSEcCtD
Rabeprazole—Confusional state—Mitoxantrone—lymphatic system cancer	0.000268	0.000991	CcSEcCtD
Rabeprazole—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000267	0.000989	CcSEcCtD
Rabeprazole—Hypotension—Carmustine—lymphatic system cancer	0.000267	0.000988	CcSEcCtD
Rabeprazole—Oedema—Mitoxantrone—lymphatic system cancer	0.000266	0.000983	CcSEcCtD
Rabeprazole—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000266	0.000983	CcSEcCtD
Rabeprazole—Nausea—Fludarabine—lymphatic system cancer	0.000265	0.000982	CcSEcCtD
Rabeprazole—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000264	0.000976	CcSEcCtD
Rabeprazole—Shock—Mitoxantrone—lymphatic system cancer	0.000261	0.000967	CcSEcCtD
Rabeprazole—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00026	0.000964	CcSEcCtD
Rabeprazole—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00026	0.000963	CcSEcCtD
Rabeprazole—Urticaria—Bleomycin—lymphatic system cancer	0.00026	0.000963	CcSEcCtD
Rabeprazole—Anorexia—Vincristine—lymphatic system cancer	0.00026	0.000962	CcSEcCtD
Rabeprazole—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000259	0.00096	CcSEcCtD
Rabeprazole—Body temperature increased—Bleomycin—lymphatic system cancer	0.000259	0.000958	CcSEcCtD
Rabeprazole—Insomnia—Carmustine—lymphatic system cancer	0.000259	0.000957	CcSEcCtD
Rabeprazole—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000257	0.000951	CcSEcCtD
Rabeprazole—Paraesthesia—Carmustine—lymphatic system cancer	0.000257	0.00095	CcSEcCtD
Rabeprazole—Hypotension—Vincristine—lymphatic system cancer	0.000255	0.000943	CcSEcCtD
Rabeprazole—Dyspnoea—Carmustine—lymphatic system cancer	0.000255	0.000943	CcSEcCtD
Rabeprazole—Somnolence—Carmustine—lymphatic system cancer	0.000254	0.00094	CcSEcCtD
Rabeprazole—Anorexia—Mitoxantrone—lymphatic system cancer	0.000253	0.000937	CcSEcCtD
Rabeprazole—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000249	0.00092	CcSEcCtD
Rabeprazole—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000249	0.00092	CcSEcCtD
Rabeprazole—Decreased appetite—Carmustine—lymphatic system cancer	0.000249	0.000919	CcSEcCtD
Rabeprazole—Hypotension—Mitoxantrone—lymphatic system cancer	0.000248	0.000919	CcSEcCtD
Rabeprazole—Insomnia—Vincristine—lymphatic system cancer	0.000247	0.000913	CcSEcCtD
Rabeprazole—Paraesthesia—Vincristine—lymphatic system cancer	0.000245	0.000907	CcSEcCtD
Rabeprazole—Constipation—Carmustine—lymphatic system cancer	0.000244	0.000904	CcSEcCtD
Rabeprazole—Pain—Carmustine—lymphatic system cancer	0.000244	0.000904	CcSEcCtD
Rabeprazole—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000243	0.000898	CcSEcCtD
Rabeprazole—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000242	0.000896	CcSEcCtD
Rabeprazole—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000241	0.000893	CcSEcCtD
Rabeprazole—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000239	0.000883	CcSEcCtD
Rabeprazole—Decreased appetite—Vincristine—lymphatic system cancer	0.000237	0.000878	CcSEcCtD
Rabeprazole—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000237	0.000877	CcSEcCtD
Rabeprazole—Somnolence—Mitoxantrone—lymphatic system cancer	0.000236	0.000874	CcSEcCtD
Rabeprazole—Feeling abnormal—Carmustine—lymphatic system cancer	0.000236	0.000872	CcSEcCtD
Rabeprazole—Asthenia—Bleomycin—lymphatic system cancer	0.000235	0.000869	CcSEcCtD
Rabeprazole—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000234	0.000866	CcSEcCtD
Rabeprazole—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000234	0.000865	CcSEcCtD
Rabeprazole—Constipation—Vincristine—lymphatic system cancer	0.000233	0.000863	CcSEcCtD
Rabeprazole—Pain—Vincristine—lymphatic system cancer	0.000233	0.000863	CcSEcCtD
Rabeprazole—Asthma—Methotrexate—lymphatic system cancer	0.000233	0.000861	CcSEcCtD
Rabeprazole—Pruritus—Bleomycin—lymphatic system cancer	0.000232	0.000857	CcSEcCtD
Rabeprazole—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000231	0.000855	CcSEcCtD
Rabeprazole—Pancreatitis—Methotrexate—lymphatic system cancer	0.000228	0.000845	CcSEcCtD
Rabeprazole—Constipation—Mitoxantrone—lymphatic system cancer	0.000227	0.000841	CcSEcCtD
Rabeprazole—Pain—Mitoxantrone—lymphatic system cancer	0.000227	0.000841	CcSEcCtD
Rabeprazole—Abdominal pain—Carmustine—lymphatic system cancer	0.000226	0.000836	CcSEcCtD
Rabeprazole—Body temperature increased—Carmustine—lymphatic system cancer	0.000226	0.000836	CcSEcCtD
Rabeprazole—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000223	0.000826	CcSEcCtD
Rabeprazole—Pancytopenia—Methotrexate—lymphatic system cancer	0.000221	0.000818	CcSEcCtD
Rabeprazole—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000219	0.00081	CcSEcCtD
Rabeprazole—Dysuria—Methotrexate—lymphatic system cancer	0.000218	0.000806	CcSEcCtD
Rabeprazole—Neutropenia—Methotrexate—lymphatic system cancer	0.000218	0.000806	CcSEcCtD
Rabeprazole—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000217	0.000804	CcSEcCtD
Rabeprazole—Abdominal pain—Vincristine—lymphatic system cancer	0.000216	0.000798	CcSEcCtD
Rabeprazole—Body temperature increased—Vincristine—lymphatic system cancer	0.000216	0.000798	CcSEcCtD
Rabeprazole—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000214	0.000793	CcSEcCtD
Rabeprazole—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000213	0.000786	CcSEcCtD
Rabeprazole—Urticaria—Mitoxantrone—lymphatic system cancer	0.000211	0.000781	CcSEcCtD
Rabeprazole—Hypersensitivity—Carmustine—lymphatic system cancer	0.000211	0.000779	CcSEcCtD
Rabeprazole—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00021	0.000777	CcSEcCtD
Rabeprazole—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00021	0.000777	CcSEcCtD
Rabeprazole—Pneumonia—Methotrexate—lymphatic system cancer	0.000209	0.000773	CcSEcCtD
Rabeprazole—Vomiting—Bleomycin—lymphatic system cancer	0.000208	0.00077	CcSEcCtD
Rabeprazole—Rash—Bleomycin—lymphatic system cancer	0.000206	0.000764	CcSEcCtD
Rabeprazole—Dermatitis—Bleomycin—lymphatic system cancer	0.000206	0.000763	CcSEcCtD
Rabeprazole—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000206	0.000762	CcSEcCtD
Rabeprazole—Asthenia—Carmustine—lymphatic system cancer	0.000205	0.000759	CcSEcCtD
Rabeprazole—Stomatitis—Methotrexate—lymphatic system cancer	0.000202	0.000749	CcSEcCtD
Rabeprazole—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000202	0.000747	CcSEcCtD
Rabeprazole—Hypersensitivity—Vincristine—lymphatic system cancer	0.000201	0.000744	CcSEcCtD
Rabeprazole—Sweating—Methotrexate—lymphatic system cancer	0.000199	0.000736	CcSEcCtD
Rabeprazole—Haematuria—Methotrexate—lymphatic system cancer	0.000198	0.000732	CcSEcCtD
Rabeprazole—Epistaxis—Methotrexate—lymphatic system cancer	0.000196	0.000725	CcSEcCtD
Rabeprazole—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000196	0.000724	CcSEcCtD
Rabeprazole—Asthenia—Vincristine—lymphatic system cancer	0.000196	0.000724	CcSEcCtD
Rabeprazole—Diarrhoea—Carmustine—lymphatic system cancer	0.000196	0.000724	CcSEcCtD
Rabeprazole—Nausea—Bleomycin—lymphatic system cancer	0.000195	0.00072	CcSEcCtD
Rabeprazole—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000194	0.000717	CcSEcCtD
Rabeprazole—Asthenia—Mitoxantrone—lymphatic system cancer	0.000191	0.000705	CcSEcCtD
Rabeprazole—Dizziness—Carmustine—lymphatic system cancer	0.000189	0.000699	CcSEcCtD
Rabeprazole—Diarrhoea—Vincristine—lymphatic system cancer	0.000187	0.000691	CcSEcCtD
Rabeprazole—Hepatitis—Methotrexate—lymphatic system cancer	0.000186	0.00069	CcSEcCtD
Rabeprazole—Pharyngitis—Methotrexate—lymphatic system cancer	0.000185	0.000684	CcSEcCtD
Rabeprazole—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000184	0.000681	CcSEcCtD
Rabeprazole—Urethral disorder—Methotrexate—lymphatic system cancer	0.000183	0.000676	CcSEcCtD
Rabeprazole—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000182	0.000673	CcSEcCtD
Rabeprazole—Vomiting—Carmustine—lymphatic system cancer	0.000182	0.000672	CcSEcCtD
Rabeprazole—Dizziness—Vincristine—lymphatic system cancer	0.00018	0.000668	CcSEcCtD
Rabeprazole—Rash—Carmustine—lymphatic system cancer	0.00018	0.000667	CcSEcCtD
Rabeprazole—Dermatitis—Carmustine—lymphatic system cancer	0.00018	0.000666	CcSEcCtD
Rabeprazole—Visual impairment—Methotrexate—lymphatic system cancer	0.00018	0.000665	CcSEcCtD
Rabeprazole—Headache—Carmustine—lymphatic system cancer	0.000179	0.000663	CcSEcCtD
Rabeprazole—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000176	0.000652	CcSEcCtD
Rabeprazole—Eye disorder—Methotrexate—lymphatic system cancer	0.000174	0.000644	CcSEcCtD
Rabeprazole—Tinnitus—Methotrexate—lymphatic system cancer	0.000174	0.000643	CcSEcCtD
Rabeprazole—Vomiting—Vincristine—lymphatic system cancer	0.000174	0.000642	CcSEcCtD
Rabeprazole—Rash—Vincristine—lymphatic system cancer	0.000172	0.000637	CcSEcCtD
Rabeprazole—Dermatitis—Vincristine—lymphatic system cancer	0.000172	0.000636	CcSEcCtD
Rabeprazole—Headache—Vincristine—lymphatic system cancer	0.000171	0.000633	CcSEcCtD
Rabeprazole—Nausea—Carmustine—lymphatic system cancer	0.00017	0.000628	CcSEcCtD
Rabeprazole—Angiopathy—Methotrexate—lymphatic system cancer	0.000169	0.000626	CcSEcCtD
Rabeprazole—Vomiting—Mitoxantrone—lymphatic system cancer	0.000169	0.000625	CcSEcCtD
Rabeprazole—Rash—Mitoxantrone—lymphatic system cancer	0.000168	0.00062	CcSEcCtD
Rabeprazole—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000167	0.000619	CcSEcCtD
Rabeprazole—Chills—Methotrexate—lymphatic system cancer	0.000167	0.000619	CcSEcCtD
Rabeprazole—Headache—Mitoxantrone—lymphatic system cancer	0.000166	0.000616	CcSEcCtD
Rabeprazole—Alopecia—Methotrexate—lymphatic system cancer	0.000165	0.000609	CcSEcCtD
Rabeprazole—Erythema—Methotrexate—lymphatic system cancer	0.000162	0.0006	CcSEcCtD
Rabeprazole—Malnutrition—Methotrexate—lymphatic system cancer	0.000162	0.0006	CcSEcCtD
Rabeprazole—Nausea—Vincristine—lymphatic system cancer	0.000162	0.0006	CcSEcCtD
Rabeprazole—Dysgeusia—Methotrexate—lymphatic system cancer	0.000159	0.000588	CcSEcCtD
Rabeprazole—Nausea—Mitoxantrone—lymphatic system cancer	0.000158	0.000584	CcSEcCtD
Rabeprazole—Back pain—Methotrexate—lymphatic system cancer	0.000157	0.000581	CcSEcCtD
Rabeprazole—Vision blurred—Methotrexate—lymphatic system cancer	0.000153	0.000566	CcSEcCtD
Rabeprazole—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000151	0.000557	CcSEcCtD
Rabeprazole—Anaemia—Methotrexate—lymphatic system cancer	0.00015	0.000555	CcSEcCtD
Rabeprazole—Malaise—Methotrexate—lymphatic system cancer	0.000146	0.000541	CcSEcCtD
Rabeprazole—Vertigo—Methotrexate—lymphatic system cancer	0.000146	0.000539	CcSEcCtD
Rabeprazole—Leukopenia—Methotrexate—lymphatic system cancer	0.000145	0.000537	CcSEcCtD
Rabeprazole—Cough—Methotrexate—lymphatic system cancer	0.000142	0.000524	CcSEcCtD
Rabeprazole—Convulsion—Methotrexate—lymphatic system cancer	0.000141	0.00052	CcSEcCtD
Rabeprazole—Myalgia—Methotrexate—lymphatic system cancer	0.000138	0.000511	CcSEcCtD
Rabeprazole—Chest pain—Methotrexate—lymphatic system cancer	0.000138	0.000511	CcSEcCtD
Rabeprazole—Arthralgia—Methotrexate—lymphatic system cancer	0.000138	0.000511	CcSEcCtD
Rabeprazole—Discomfort—Methotrexate—lymphatic system cancer	0.000136	0.000505	CcSEcCtD
Rabeprazole—Confusional state—Methotrexate—lymphatic system cancer	0.000134	0.000494	CcSEcCtD
Rabeprazole—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000132	0.00049	CcSEcCtD
Rabeprazole—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.00013	0.00048	CcSEcCtD
Rabeprazole—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000128	0.000474	CcSEcCtD
Rabeprazole—Anorexia—Methotrexate—lymphatic system cancer	0.000126	0.000467	CcSEcCtD
Rabeprazole—Hypotension—Methotrexate—lymphatic system cancer	0.000124	0.000458	CcSEcCtD
Rabeprazole—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000121	0.000446	CcSEcCtD
Rabeprazole—Insomnia—Methotrexate—lymphatic system cancer	0.00012	0.000443	CcSEcCtD
Rabeprazole—Paraesthesia—Methotrexate—lymphatic system cancer	0.000119	0.00044	CcSEcCtD
Rabeprazole—Dyspnoea—Methotrexate—lymphatic system cancer	0.000118	0.000437	CcSEcCtD
Rabeprazole—Somnolence—Methotrexate—lymphatic system cancer	0.000118	0.000436	CcSEcCtD
Rabeprazole—Dyspepsia—Methotrexate—lymphatic system cancer	0.000117	0.000431	CcSEcCtD
Rabeprazole—Decreased appetite—Methotrexate—lymphatic system cancer	0.000115	0.000426	CcSEcCtD
Rabeprazole—Pain—Methotrexate—lymphatic system cancer	0.000113	0.000419	CcSEcCtD
Rabeprazole—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000109	0.000404	CcSEcCtD
Rabeprazole—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000108	0.000401	CcSEcCtD
Rabeprazole—Urticaria—Methotrexate—lymphatic system cancer	0.000105	0.000389	CcSEcCtD
Rabeprazole—Abdominal pain—Methotrexate—lymphatic system cancer	0.000105	0.000387	CcSEcCtD
Rabeprazole—Body temperature increased—Methotrexate—lymphatic system cancer	0.000105	0.000387	CcSEcCtD
Rabeprazole—Hypersensitivity—Methotrexate—lymphatic system cancer	9.76e-05	0.000361	CcSEcCtD
Rabeprazole—Asthenia—Methotrexate—lymphatic system cancer	9.5e-05	0.000351	CcSEcCtD
Rabeprazole—Pruritus—Methotrexate—lymphatic system cancer	9.37e-05	0.000347	CcSEcCtD
Rabeprazole—Diarrhoea—Methotrexate—lymphatic system cancer	9.06e-05	0.000335	CcSEcCtD
Rabeprazole—Dizziness—Methotrexate—lymphatic system cancer	8.76e-05	0.000324	CcSEcCtD
Rabeprazole—Vomiting—Methotrexate—lymphatic system cancer	8.42e-05	0.000311	CcSEcCtD
Rabeprazole—Rash—Methotrexate—lymphatic system cancer	8.35e-05	0.000309	CcSEcCtD
Rabeprazole—Dermatitis—Methotrexate—lymphatic system cancer	8.34e-05	0.000309	CcSEcCtD
Rabeprazole—Headache—Methotrexate—lymphatic system cancer	8.3e-05	0.000307	CcSEcCtD
Rabeprazole—Nausea—Methotrexate—lymphatic system cancer	7.87e-05	0.000291	CcSEcCtD
